Sökning: onr:"swepub:oai:DiVA.org:liu-116611" >
HSP60 predicts surv...
HSP60 predicts survival in advanced serous ovarian cancer.
-
- Hjerpe, Elisabet (författare)
- Karolinska Institutet
-
- Egyhazi, Suzanne (författare)
- Karolinska Institutet
-
- Carlson, Joseph (författare)
- Karolinska Institutet
-
visa fler...
-
- Stolt, Marianne Frostvik (författare)
- Department of Oncology and Pathology, Cancer Center Karolinska CCK R8:03, Karolinska Institutet, Stockholm, Sweden
-
- Schedvins, Kjell (författare)
- Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden
-
- Johansson, Hemming (författare)
- Karolinska Institutet
-
- Shoshan, Maria (författare)
- Karolinska Institutet
-
- Åvall-Lundqvist, Elisabeth (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Lippincott Williams & Wilkins, 2013
- 2013
- Engelska.
-
Ingår i: International Journal of Gynecological Cancer. - : Lippincott Williams & Wilkins. - 1048-891X .- 1525-1438. ; 23:3, s. 448-455
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVE: Heat shock protein 60 (HSP60) plays an essential role in malignant cell survival. We evaluated the prognostic and treatment predictive value of HSP60 in advanced ovarian cancer.METHODS: Fresh tumor samples were prospectively collected from 123 patients undergoing primary surgery for suspected advanced ovarian cancer. Of these, 57 fulfilled the eligibility criteria, that is, International Federation of Gynecology and Obstetrics stage IIC-IV, serous/endometrioid tumors, platinum-based chemotherapy, and specimens with 50% tumor cells or greater. Heat shock protein 60 mRNA and protein expression was determined by real-time polymerase chain reaction and immunohistochemistry. We estimated the association between HSP60 and overall survival (OS) and platinum-free interval (PFI) by Cox proportional hazards models and its relationship with treatment response by Fisher's exact test. Median follow-up was 60 months.RESULTS: High HSP60 mRNA expression was associated with shorter OS (hazard ratio [HR], 3.4; 95% confidence interval [CI], 1.3-8.5) and PFI (HR, 3.3; 95% CI, 1.5-7.2). Likewise, high HSP60 protein expression was associated with shorter OS (HR, 3.2; 95% CI, 1.5-7.1) and PFI (HR, 2.6; 95% CI, 1.3-5.3). Median survival for patients with high HSP60 protein expression was 31 months compared with 55 months for low expression cases (P = 0.016). The impact on OS and PFI was even stronger in the subgroup of grade 3 serous tumors. All patients with low HSP60 levels responded to first-line chemotherapy.CONCLUSION: Heat shock protein 60 may identify groups of advanced serous ovarian cancer with different prognosis and treatment response.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reproduktionsmedicin och gynekologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Obstetrics, Gynaecology and Reproductive Medicine (hsv//eng)
Nyckelord
- HSP60
- Ovarian cancer
- Real-time PCR
- Immunohistochemistry
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas